$5.50 +0.0900 ( +1.65% ) 129.0K
NASDAQ : LTRN
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Our lead development programs include two Phase 2 clinical programs and multiple upcoming Phase 1 clinical trials anticipated for 2023. We have also established a wholly-owned subsidiary, Starlight Therapeutics Inc., to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates are estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world.
Value Proposition
Lantern Pharma is revolutionizing the fields of oncology drug discovery and development through its proprietary AI and machine learning platform, RADR®. Utilizing an extensive dataset of over 25 billion oncology-centric data points and a library of more than 200 advanced machine learning algorithms, the company addresses multi-billion-dollar challenges in the oncology drug development landscape. With guidance from an elite team of scientific advisors and collaborators, Lantern Pharma has expedited its growing portfolio of treatments. This includes eleven distinct cancer indications as well as an antibody-drug conjugate program. Remarkably, new drug programs propelled by Lantern Pharma's technology advance from initial AI-derived insights to first-in-human clinical trials within a 2-3 year time frame and at a cost of approximately $1.0-2.0 million per program. The company's AI-empowered pipeline has an estimated combined annual market potential exceeding $15 billion USD and holds the promise of delivering transformative therapies to hundreds of thousands of cancer patients.
Market Data
Investment Highlights
- RADR® is among the world’s largest, most comprehensive and fastest growing AI-based oncology drug discovery and development platforms, with over 25 billion data points and 200+ algorithms powering a wide range of cancer drug development issues.
- Advanced clinical pipeline addressing several multi-billion-dollar cancer indications in challenging and rare cancers with multiple FDA granted orphan drug designations and a rare pediatric designation.
- 80 issued patents and pending patent applications across 14 patent families covering composition of matter, methods of use, biomarker signatures and the core AI platform.
- Collaborations with world-renowned cancer researchers including Georgetown, Johns Hopkins, Fox Chase Cancer Center, The National Cancer Institute, Danish Cancer Society Research Center, and UT Health: Greehey Children’s Cancer Research Institute.
- Growing portfolio in 2 key areas: A.I. driven internally developed ADC programs and collaborative development portfolio which leverages RADR® in partnership with biopharma companies.
- Initial data from Phase 2 trial in metastatic castration resistant prostate cancer (mCRPC) with LP-100 showed a median overall survival of 12.7 months – and plans to move to an earlier, 2nd line, setting with PARP inhibitors.